Activating *ABCC8* mutations are responsible of neonatal diabetes mellitus (NDM) ([@B1]--[@B5]) and late-onset diabetes with variable clinical phenotypes ([@B2],[@B4],[@B6],[@B7]). Sulfonylurea (SU) drugs bind the high-affinity pancreatic β-cell--expressed sulfonylurea receptor (SUR 1) (encoded by *ABCC8*) of the ATP-sensitive K^+^ channels (K~ATP~ channels) and close them, subsequently stimulating insulin secretion ([@B8]). SU treatment may successfully replace insulin to control diabetes during the neonatal period ([@B2],[@B9],[@B10]).

Here, we report detailed clinical and metabolic investigations in seven adult carriers of gain-of-function *ABCC8* mutations ([@B2],[@B7],[@B11]), of whom five developed late-onset diabetes diagnosed between the ages of 14 and 39 years. We also screened an adult outpatient cohort with type 2 diabetes well controlled by SU for *ABCC8* mutations.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Two populations were studied. A family-based study included four patients with adulthood developing-onset diabetes, who were relatives of a child with NDM because of a previously identified *ABCC8* mutation ([@B2],[@B11]), and one adult patient and his two children who carry the same *ABCC8* mutation ([@B7]) ([Table 1](#T1){ref-type="table"}). From an adult type 2 diabetic outpatient cohort, 139 patients who were well controlled with SU were analyzed for *ABCC8* sequencing ([Supplementary Data](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)). Written, informed consent was obtained from all patients
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*ABCC8* gene sequencing {#s6}
-----------------------

All *ABCC8* exons and flanking intron-exon boundaries were amplified from a genomic DNA sample and directly sequenced by double-stranded Sanger sequencing, as previously described ([@B2]). Each mutation identified from the reference sequence, NM_000352.3, was confirmed by resequencing the original sample. The frequency of two mutations was assessed in a French general population by using the high-resolution melting genotyping method ([Supplementary Data](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)).

Metabolic studies {#s7}
-----------------

Insulin secretion was evaluated during oral or intravenous glucose tolerance tests and by graded glucose infusion and arginine tests ([@B12]). Insulin sensitivity was assessed using a euglycemic-hyperinsulinemic clamp ([Supplementary Data](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)).

RESULTS {#s8}
=======

Seven subjects from four families ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)) were studied: five patients with diabetes, of whom two were successfully switched from insulin to SU, one subject presenting with glucose intolerance and one with normal glucose tolerance. Their clinical and genetic characteristics are shown in [Table 1](#T1){ref-type="table"}.

During the graded glucose infusion, the four investigated patients had a low insulin secretion rate (ISR) at the 10 mmol/L plateau; at the 15 mmol/L glucose level, two patients remained in the low to normal range, whereas two other subjects exhibited a normal ISR ([Supplementary Fig. 2*A*](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)). Three of four patients studied responded normally to the arginine test ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)). In two patients, early insulin response (EIR) after the oral glucose tolerance test was blunted or low compared with control subjects. In two other patients who underwent the intravenous glucose tolerance test, the acute insulin response to glucose was blunted, whereas after a 4-week SU treatment (7.5 and 15 mg/day glyburide, respectively), it increased by 2.5- and 22-fold, respectively ([Supplementary Fig. 2*B*](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)). The glucose disposal rate (or *M* value) was low in two patients, and the derived insulin sensitivity index was comparable with control subjects, except in one obese patient ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)). Finally, the disposition index was low in the glucose-intolerant patient compared with control subjects ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1)).

Four patients with adult-onset type 2 diabetes from the cohort study carried a heterozygote missense *ABCC8* mutation ([Table 1](#T1){ref-type="table"}). Three mutations were previously reported (c.2476C\>T/p.R826W in transient NDM \[TNDM\] ([@B3],[@B4],[@B13]), c.1252T\>C/p.C418R and c.1858C\>T/p.R620C in congenital hyperinsulinism \[CHI\] ([@B14],[@B15])), and one mutation is novel (c.601C\>G/p.P201S). No relatives of these patients were available for mutation testing. The P201S mutation that lies at a highly conserved residue across mammalian species, in the L0-linker loop of the TMD0-L0 gatekeeper module of SUR1 ([@B16]), was not present in 330 normoglycemic French subjects. TMD0-L0 was proposed to transduce Mg-nucleotide stimulation and high-affinity SU inhibition from the SUR1 core to the Kir6.2 pore ([@B17]). Genotyping of C418R and R620C mutations in \>4,000 normoglycemic individuals from the French Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.) cohort ([@B18]) identified five and one carrier, respectively, suggesting that they may represent rare variants (population carrier frequency of 0.06 and 0.012%) likely not related to disease.

CONCLUSIONS {#s9}
===========

Our study strengthens the findings that *ABCC8* mutations cause variable clinical phenotypes with glucose intolerance, overt diabetes, or insulin-requiring diabetes from a young age to adulthood. Several factors may explain this variability, also seen within families, such as the type and location of the mutation itself or other modifier genetic and superimposed environmental factors ([@B2],[@B6]). Impaired insulin secretion in response to glucose is a major metabolic feature in adult *ABCC8* mutation carriers, whereas insulin secretion in response to arginine is relatively preserved in keeping with K~ATP~ channel--independent mechanisms for insulin exocytosis. As expected, SU treatment as a monotherapy provided good glycemic control in five adult diabetic patients, in accordance with previous reports in children ([@B2],[@B9],[@B10]).

A pathogenic role for three mutations (C435R, L582V, and R1380H) is very likely, because NDM was diagnosed in family relatives (this study) or reported by other studies ([@B2],[@B4],[@B11]). The previously published Y356C and R826W mutations ([@B4],[@B6],[@B7],[@B13]) were functionally demonstrated to alter MgATP sensitivity or ATPase activity of SUR1, respectively, leading to K~ATP~ channel activation with increased resting whole-cell currents ([@B7],[@B13]). We cannot exclude that two rare variants (C418R and R620C), as previously reported in CHI ([@B14],[@B15]) and found here in two diabetic patients, are nonfunctional (i.e., nondeleterious). An earlier study reported a dominant form of CHI attributed to the E1507K-*ABCC8* mutation, which is responsible for decreased insulin secretory capacity and diabetes in middle age ([@B19]).

Identifying an *ABCC8* mutation in adult relatives of NDM patients will have significant clinical implications; insulin therapy may be successfully replaced by oral SU in idiopathic type 1 diabetes, and type 2 diabetic patients could be better treated by SU rather than other drugs such as incretins. However, from our study, the occurrence of likely causal *ABCC8* mutations in adult-onset type 2 diabetes well-controlled by SU is low (\~1--1.5%). Another important issue is genetic counseling in the rest of the family.

Translation of these results into medical practice would be to search for *ABCC8* mutations in adult patients with a family history of NDM or hyperinsulinism of infancy and in type 2 diabetic patients who are not overweight but have a dominant pattern of diabetes inheritance (patients with unexplained maturity-onset diabetes of the young). With the progress of targeted next-generation sequencing, the recognition of a diabetes genetic subtype is of great interest for genuine personalized medicine.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1469/-/DC1>.
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